Other substances

N-[(1R)-2-(Tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide

An aromatic amide.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

N-[(1R)-2-(Tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide is a drug originally designed as a SARS-CoV 3C-like protease inhibitor (Jacobs et al., 2013).

N-[(1R)-2-(Tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide on PubChem

Synonyms

ML188

 

Structure image - N-[(1R)-2-(Tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide

CC(C)(C)C1=CC=C(C=C1)N([C@H](C2=CN=CC=C2)C(=O)NC(C)(C)C)C(=O)C3=CC=CO3

Supporting references

Link Tested on Impact factor Notes Publication date
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
3CLpro Crystallization Enzyme assay In vitro 		in vitro enzyme assay; crystallization 3.82

The compound inhibited the SARS-CoV-2 3C-like protease in vitro with an IC50 of ca. 2.5 μM. Co-crystallized with the enzyme, there were structural indicators of improved noncovalent binding of the compound to the SARS-CoV2 3C-like protease compared to the SARS-CoV 3C-like protease.

 Jan/25/2021
Export (.csv)